A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Inclusion Criteria:

Note: Participants aged 16 or 17 may enroll in M14-234 or M14-675 where locally permissible

• Participant has not achieved clinical response at the end of the induction period (Week 8) in Study M14-234 Substudy 1, has had loss of response during themaintenance period of Study M14-234 Substudy 3, or has successfully completed StudyM14-234 Substudy 3. During the COVID-19 pandemic, for participants with missingendoscopy at Week 8, Week 16 or Week 52 due to the COVID-19 pandemic in StudiesM14-234 Substudy 2, M14-234 Substudy 3 and M14-675, participants may be enrolled ifcertain criteria are met.

• If female, participant must meet the contraception criteria.

• Women of childbearing potential must have a negative urine pregnancy test at Week 0visit.

• Participant is judged to be in otherwise good health as determined by the principalinvestigator based upon clinical evaluations performed during the preceding study (Study M14-234).

• Must be able and willing to give written informed consent and to comply with therequirements of this study protocol.

Exclusion Criteria:

• For any reason participant is considered by the investigator to be an unsuitablecandidate.

• Female participant with a positive pregnancy test at the final visit of StudyM14-234 or who is considering becoming pregnant during the study or within 30 daysafter the last dose of study drug.

• Known hypersensitivity to upadacitinib or its excipients or had any adverse event (AE) during the preceding studies, that in the investigator's judgment makes theparticipant unsuitable for this study.

• Participant with an active or recurrent infection that based on the investigator'sclinical assessment makes the participant an unsuitable candidate for the study.Participants with ongoing infections undergoing treatment may be enrolled BUT NOTdosed until the infection has been successfully treated.

• Current evidence of active tuberculosis (TB); current evidence of latenttuberculosis and for any reason the participant cannot take full course of TBprophylaxis treatment as required per protocol.

• Participant with a poorly controlled medical condition, such as uncontrolleddiabetes, unstable ischemic heart disease, moderate or severe congestive heartfailure (New York Heart Association class III or IV), recent cerebrovascularaccidents and any other condition which, in the opinion of the investigator orsponsor, would put the subject at risk by participation in this study.

• Participants have malignancy, high-grade dysplasia, un-removed low-grade dysplasiaof the gastrointestinal tract diagnosed at the endoscopy performed at the finalvisit of Study M14-234.

• History of any malignancy except for successfully treated nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix from evaluations performed inStudy M14-234.